Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.6001
-0.0750 (-11.11%)
At close: Aug 1, 2025, 4:00 PM
0.6100
+0.0099 (1.65%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Windtree Therapeutics Employees
Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,482,071
Market Cap
7.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | -6 | -30.00% |
| Dec 31, 2022 | 20 | -13 | -39.39% |
| Dec 31, 2021 | 33 | 2 | 6.45% |
| Dec 31, 2020 | 31 | -1 | -3.13% |
| Dec 31, 2019 | 32 | -1 | -3.03% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
WINT News
- 4 days ago - Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - GlobeNewsWire
- 9 days ago - Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy - GlobeNewsWire
- 17 days ago - Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions - GlobeNewsWire
- 4 weeks ago - Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - GlobeNewsWire
- 5 weeks ago - Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - GlobeNewsWire
- 2 months ago - Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - GlobeNewsWire
- 2 months ago - Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - GlobeNewsWire
- 3 months ago - Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - GlobeNewsWire